

JOHNSON & JOHNSON
SELECTED PHARMACEUTICALS IN LATE STAGE U.S. and E.U. DEVELOPMENT OR REGISTRATION
As of April 17, 2012*

Therapeutic Area	Product Name	Indication Sought	U.S. Development Stage	E.U. Development Stage
Cardiovascular and Metabolism	XARELTO® (rivaroxaban)	VTE treatment (2) Acute Coronary Syndrome (2)	Phase III Filed 12/11	
	canagliflozin	Type 2 diabetes (2) Fixed Dose Combination with Metformin	Phase III Phase III	Phase III Phase III
	PRILIGY (dapoxetine)	Premature ejaculation (2)	FDA non-approvable letter 10/05	EC Confirmed Positive CHMP Opinion 1/12
Immunology	REMICADE® (infliximab)	Pediatric Ulcerative Colitis	Approved 9/11	Approved 2/12
	STELARA® (ustekinumab)	Psoriatic Arthritis Crohn's Disease	Phase III Phase III	Phase III Phase III
	SIMPONI® (golimumab)	Rheumatoid Arthritis (IV) Structural Damage (RA) Structural Damage (PsA) Ulcerative Colitis	Phase III FDA Complete Response letter 7/11 FDA Complete Response letter 9/11 Phase III	Filed 11/11 Approved 1/11 Approved 5/11 Phase III
Infectious Diseases and Vaccines	DORIBAX™ (doripenem)	Nosocomial Pneumonia (2)	FDA Complete Response letter 8/08 FDA Second Complete Response 10/10	Approved 7/08
	PREZISTA® (darunavir)	HIV 800 mg tablet for treatment naïve patients and treatment experienced patients	Filed 1/12	Filed 1/12
	TMC435	Chronic hepatitis C virus (HCV) infection for treatment naïve patients and relapsers Chronic hepatitis C virus (HCV) infection for treatment experienced patients and relapsers	Phase III Phase III	Phase III Phase III
Neuroscience	NUCYNTA® ER (tapentadol)	Diabetic peripheral neuropathy (Extended Release formulation) (2)	Filed 10/11	
	INVEGA® (paliperidone ER OROS)	Pediatric indication - adolescent schizophrenia	Approved 4/11	Phase III
	bapineuzumab	Mild to moderate Alzheimer's disease (3)	Phase III	
Oncology	PROCRIPT® (epoetin alfa)	Chronic Renal Function - extended dosing (2)	Supplemental application withdrawn 1/12	Filed 4/10
	VELCADE® (bortezomib)	Non-Hodgkin's Lymphoma (2) Mantle Cell Lymphoma 1st line (2) Subcutaneous formulation		Filed 9/11 Phase III Filed 3/11
	YONDELIS® (trabectedin)	Soft Tissue Sarcoma	Phase III	
	ZYTIGA® (abiraterone acetate)	Prostate cancer chemo naïve	Phase III	Phase III
	DACOGEN® (decitabine) for Injection	Acute Myeloid Leukemia (2)		Filed 5/11

* This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

(2) Doribax™ developed in collaboration with Shionogi & Co., canagliflozin licensed from Mitsubishi Tanabe Pharma Corporation; Procrit®/Eprex® licensed from Amgen Inc., Velcade® developed in collaboration with Millennium Pharmaceuticals, The Takeda Oncology Company, Yondelis® developed in collaboration with PharmaMar, Dacogen® developed in collaboration with Eisai Corporation of North America, Nucynta® co-developed with Grunenthal GMBH, Xarelto® co-developed with Bayer HealthCare, Priligy® developed in collaboration with Furiex Pharmaceuticals, and TMC435 developed in collaboration with Medivir AB.

(3) bapineuzumab acquired from Elan Pharmaceuticals plc and being developed in collaboration with Pfizer

MD&D Pipeline Highlights –Orthopaedics, Diabetes Care, Diagnostics, Infection Prevention/Other, Vision Care

2011/2012 Approved/Cleared

Orthopaedics

COUGAR® LS Lateral Cage
VIPER® LX
EXPEDIUM® LX
RECLAIM™ Hip Revision (EU)
Shoulder Fracture Platform (EU)
AOX Poly for Sigma® and LCS
PINNACLE® CoMplete® Acetabular Hip System (US²)
TRUMATCH™ (US)
SIGMA® PS150 (EU, Japan)
DVR Express (US)
Next Generation DVR® Wrist Plate (US)
CERTAS™ Programmable Shunt (US)
GRIPTION TF™ (TIFOAM) Hip and Knee (EU)

Diabetes Care

ONETOUGH® VERIO™ Blood Glucose System Version 1 (US)
ANIMAS® VIBE™ Insulin Pump and CGM System (CE Mark)
ONETOUGH® VERIO™ Blood Glucose System Version 2.5 (US/EU)
Next Generation POC Testing System (EU)

Diagnostics

VITROS® 4600 System¹
ORTHO VERSEIA™ Pipetter (US)
ORTHO VERSEIA™ Pipetter Assays (US¹)
New VITROS® Assay:
- Hepatitis B e-antigen and antibody
-Syphilis (EU)

Infection Prevention/Other

SEDASYS® System (EU)
GLOSAIR™ 600 System (US)⁴
STERRAD® 100NX® System (Japan)

Pending Approval

Orthopaedics

CAIS Cartilage Regeneration (EU)

Diabetes Care

Infection Prevention/Other

SEDASYS® System (US^{2,5})

2012 Planned Submissions

Orthopaedics

Next Generation Knee System
DVR Express (EU)
Next Generation DVR® Wrist Plate (EU)
Expedium FAS 2

Diabetes Care

Animas® Vibe™ Insulin Pump and CGM System (PMA³)
OneTouch® Verio™ Blood Glucose System Version 3
Next Generation ONETOUGH® Ping (US)
Next Generation POC Testing System (Japan)

Diagnostics

New VITROS® Assays:
-Vitamin D
-Prostate-specific antigen² (tPSA & fPSA – EU only)
Rare Sera Assays for ORTHO BioVue® and AutoVue® (EU notified body review)

Infection Prevention/Other

Next Gen High-Level Disinfection (EU)

2013+ Planned Submissions

Orthopaedics

New Poly Hip Bearings
Next Generation Hip System
Next Generation Shoulder
CAIS Cartilage Regeneration (US²)
ReVive™ SE (US)
OV Shoulder
Bone Preserving Hip Stem
DeltaMotion® Hip System (US²)

Diabetes Care

Next Generation POC Testing System Version 1.5 (EU, Japan)

Next Generation Platform Version 1

Diagnostics

New VITROS® Assays:
-HIV Combo²
Next Generation VITROS® System
Transfusion Medicine Platform
CELLEX™ System: Crohn's Disease and Graft-versus-host disease²

Infection Prevention/Other

GLOSAIR™ 600 System (EU⁴)

Vision Care

Anti-allergy drug with a contact lens (US⁶)

Selective Highlights as of 4/17/012. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Filings/approvals assumed to be U.S. 510K and EU CE Mark unless otherwise noted.

¹ US Regulatory submission based on FDA filing for current platforms

² US PMA filing

³ In collaboration with DexCom. DexCom is PMA holder.

⁴ US -GLOSAIR™ Systems released using EPA-cleared Sanosil S010 Solution. EU - GLOSAIR™ 600 System will require EU CE Mark to Machinery Directive. GLOSAIR™ 600 Solution will require registration in each country per local regulatory/registration requirements.

⁵ FDA Approvable Letter received 2/12

⁶ US NDA filing

MD&D Pipeline Highlights – General Surgery, Specialty Surgery, Cardiovascular Care

2011 /2012 Approved/Cleared

General Surgery

ETHICON SECURESTRAP™ 5mm Strap Fixation Device (EU)

DERMABOND™ Advanced

EVERPOINT™ Cardiovascular Needles

PDS™ PLUS Barbed Suture

5mm ENDOPATH® XCEL with OPTIVIEW® Technology

ECHELON™ FLEX Powered ENDOPATH® Stapler 60 MM (US)

Tissue Approximating Fastener – 5LMS

Percutaneous Surgical Set (EU)

Verv® System – NMS technology for OAB (EU)

DERMABOND™ Mini

Cardiovascular Care

EXOSEAL™ VCD (CE Mark)

THERMOCOOL® SF Irrigated Catheter (Japan)

PRESILLION™ Plus Bare Metal Stent (CE Mark)

CARTOSOUND™ (Japan)

EXOSEAL™ VCD (US1)

CARTO® 3 V2 Navigation Technology (US² & CE Mark)

THERMOCOOL® SF Irrigated Catheter (US.)

Specialty Surgery

ENSEAL® G2 Super Jaw (US/EU)

EES Generator – HARMONIC® and ENSEAL® Combination Generator (US/EU)

ENSEAL® Next Generation Tissue Sealers (8 product codes) (US, EU)

Acclarent™ – CYCLOPS™ Multi-Angle Endoscope

SURGIFLO® with Integrated Thrombin Kit (EU)

Acclarent™– TULA™ Tube Delivery System (US)

Acclarent™– TULA™ Iontophoresis System (US)

Acclarent™– SPIN Integrated Balloon Sinuplasty Solution (US)

Acclarent™– *Relieva Ultirra™* Sinus Balloon Catheter (US)

SURGIFLO® with Integrated Thrombin Kit (US(BLA/PMA))

Pending Approval

General Surgery

GYNECARE Next Generation Pelvic Floor Repair Kit (US)

Percutaneous Surgical Set (US)

Verv® System – NMS technology for OAB (US)

Specialty Surgery

Fibrin Pad (US BLA)²

Acclarent – TULA™ Additional Indications

HARMONIC® Next Gen Lap Shears Platform (US)

Fibrin Pad (EU)

Cardiovascular Care

EXOSEAL™ VCD (Japan)

S.M.A.R.T.® Stent for SFA (PMA Supp)

POWERFLEX™ Pro PTA Balloon Next Generation

nMARQ™ Circular Ablation (CE Mark)

THERMOCOOL® SMARTTouch® Contact Force Catheter (Japan)

INCRAFT™ AAA Stent Graft (CE Mark)

2012 Planned Submissions

General Surgery

Metabolics

11/12mm ENDOPATH® XCEL with OPTIVIEW® Technology

ETHICON SECURESTRAP™ Open

Ventral Hernia Device

GYNECARE MORCELLEX™ Sigma ECHELON™ FLEX Powered ENDOPATH® Stapler 45MM (US)

Specialty Surgery

HARMONIC® Next Gen Lap Shears Platform (EU)

ENSEAL® Next Gen Innovation 1 (US/EU)

ENSEAL® Next Gen Innovation 2 (US/EU)

Cardiovascular Care

CARTO® 3 V3 Navigation Technology

nMARQ™ Circular Ablation (US¹)

2013+ Planned Submissions

General Surgery

VICRYL RAPIDE™ Plus Suture
Additional PLUS Barbed Suture
GYNECARE SUI Sling Next Generation

Specialty Surgery

Fibrin Pad (Additional Indications)
MENTOR® Purified Toxin (US BLA)

Cardiovascular Care

THERMOCOOL® SMARTTouch® Contact Force Catheter (US¹)

INCRAFT™ AAA Stent Graft (US² & Japan)

Selective Highlights as of 4/17/2012. This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. Filings/approvals assumed to be U.S. 510K and EU CE Mark unless otherwise noted.

¹ US PMA filing

² FDA Approvable Letter received 2/12